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Abstract
The amyloid-beta (Aβ) protein is known to play an important role in the etiology of
Alzheimer’s disease (AD). Aβ peptide aggregates in the brains of AD patients to form
soluble oligomers as well as insoluble fibrils. Oligomers of Aβ are now known to be the
primary toxic agents in AD. Evidence is beginning to emerge regarding a conserved
prion-like propagation mechanism in AD. One of the principal characteristics of prion
diseases is their ability to self-propagate via a template-assisted-corruptive mechanism.
Our lab has previously characterized a unique ‘Aβ prion’ called Large Fatty-AcidDerived Oligomers (LFAOs). This project examines the ability of LFAOs to selfpropagate and cross-seed the formation of aggregates among mutant varieties of the
peptide.

We observed the self-seeding and cross-seeding reactions of wild-type and

Arctic (E22G) mutant varieties of LFAOs. Self-seeding of wild-type Aβ (1-42) (Aβ42)
generated an increase in the amount of oligomer of the same size as the formed LFAOs,
as did the cross-seeding of wild-type Aβ42 monomer with E22G LFAOs. Self-seeding of
E22G monomer with E22G LFAOs, however, resulted in much larger aggregates. Crossseeding of Aβ (1-40) (Aβ40) monomer with E22G LFAOs resulted in the formation of
more oligomer of the same size as the seed. In addition, we have examined the stability
of LFAOs in various experimental conditions.
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Introduction
Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder found most often in
patients above the age of 60. It is the most common form of dementia, affecting an
estimated 5.4 million people nationwide. 1 Although it occurs often in patients with no
family history of the disease, familial factors can also play a role in the disease’s
development. 2 A progressive disorder, AD causes the death of neuronal cells, leading to
a gradual decline in cognitive function. AD patients experience memory loss, difficulty
completing familiar tasks, and confusion with regards to time and place. AD is at this
time considered incurable, and the progression of symptoms eventually results in death.
Amyloid-beta (Aβ) in Alzheimer’s disease
Brains of post mortem AD patients show large amounts of insoluble proteinacious
‘senile’ plaques, as do the brains of patients with similar neurodegenerative disorders. A
major component of these plaques is the aggregates of a peptide called Aβ, and evidence
suggests that this peptide plays an important role in the development of AD. Amyloid
beta (Aβ) is the result of the cleavage of the trans-membrane protein known as the
amyloid precursor protein (APP). 3 A pair of aspartyl secretases, β and, sequentially
cleave APP to generate Aβ peptides with varying lengths (39-43). Among these, Aβ 1-40
(Aβ40) and Aβ1-42(Aβ42) are the most abundantly produced, and form the principal
components of the senile plaques.

AD is largely a sporadic disease with only ~ 10-15%

being familial. 3. Mutations in the genes encoding APP can cause an individual to
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develop AD, as can the over-expression of the normal APP gene such as that present in
patients with Down’s syndrome. 2, 4
Aβ mutants and cerebral amyloid angiopathy
In addition to neuronal degeneration, AD patients are also at an increased risk for
cerebral amyloid angiopathy (CAA). CAA is a condition in which neuritic plaques build
up in the brain vasculature, leading to ischemic stroke. Several mutant Aβ peptides are
associated with CAA pathology. These include the Arctic (E22G), Italian (E22K), and
Dutch (E22Q) varieties.5

Patients carrying a point mutation resulting in a change of the

22nd position of the Aβ peptide, particularly a substitution of glutamine for glutamic acid,
have been shown to be at increased risk for CAA. 6 In addition, the Arctic mutant of the
Aβ peptide, carrying a substitution of glycine for glutamic acid at the 22 nd position, has
been shown to exhibit enhanced protofibril formation. 7
Oligomeric species toxicity
For several years after their discovery, amyloid plaques were thought to be the
major causative agent in AD. 8 Lue and co workers found that the correlation between
the amount of soluble Aβ present in the post-mortem brains of AD patients and the extent
of synaptic change was much stronger than that between the accumulation of neuritic
plaques and synaptic change. 9 Kuo and co workers found that the amount of watersoluble Aβ, particularly Aβ42, present in the brain of AD individuals was 12 times the
amount found in non-AD brains. 10 These results suggest that soluble Aβ is much more
likely the primary cause of neurodegeneration in AD than the insoluble fibril form of Aβ.
The findings of Lambert and co workers supported this evidence, by demonstrating that
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soluble Aβ oligomers are neurotoxic in the absence of any fibril forms of Aβ. 11 Walsh
and co workers demonstrated that naturally secreted human Aβ oligomers inhibit longterm potentiation, a process involved with the formation of memories, in mice. 12
Formation of soluble oligomers
In order to design effective treatments for AD, it is important that we understand
the pathways by which neurotoxic soluble oligomers are formed. Barghorn and co
workers demonstrated that a globular oligomer (globulomer) of Aβ42 could be formed in
a pathway independent of that of fibril formation. 13 They incubated synthetic Aβ42 in
0.2% sodium dodecyl sulfate (SDS), producing and intermediate which was able to selfaggregate to a globulomer form. Rabbits were immunized against these globulomers, and
the resulting antibodies were used to demonstrate that this globular form of Aβ exists in
the brains of AD patients. They also determined that certain fatty acids could be used to
produce the globular form.
Walsh and co workers demonstrated that soluble Aβ oligomers are formed
intracellularly in the human brain. 14 After previously demonstrating that Aβ oligomers
are present in intracellular spaces, they conducted a series of trials in which monomeric
forms of Aβ failed to produce oligomeric forms in CSF incubated at 37°C. They also
acquired 56 human CSF samples, which they tested for the presence of oligomeric forms
of Aβ using immunoprecipitation. They found soluble oligomeric forms of Aβ in 15 of
the 56 samples. This would seem to indicate that formation of Aβ oligomers begins
intracellularly, but that oligomers are at some point released to extracellular spaces.
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Gellerman and co workers showed that globular formation proceeds
independently of the fibril formation pathway. 15 They observed that the presence of Aβ
fibrils was able to initiate fibril formation in monomeric Aβ, but did not induce fibril
formation of Aβ globulomers. They also investigated the effects of known inhibitors of
fibril formation on the formation of globulomeric Aβ, and found that fibril inhibitors did
not affect the formation of globulomers. They speculate that because it is possible to
produce inhibitors for the two pathways separately, it might eventually be possible to
generate a vaccine to inhibit oligomer formation without producing the side-effects
associated with targeting fibril plaques.
Chromy and co workers investigated the ability of Aβ to self-aggregate to
oligomeric forms as well as the toxicity of the formed species. 16 They found that Aβ was
able to assume several oligomeric forms in the absence of fibrils, and demonstrated that
some of these oligomers have toxic effects on cells while others do not, suggesting that
multiple oligomeric forms are possible. They also examined the possible neuroprotective
effects of extracts of Ginkgo biloba, and found that these extracts were able to retard the
formation of oligomers over short incubation times, but that oligomers formed after
longer incubations.
Kumar and co workers investigated a method of producing oligomers using
substances that are present under physiological conditions. 17 They used non-esterified
fatty-acids, rather than the previously favored SDS, to produce low molecular weight
oligomers via two different pathways. They first determined the critical micelle
concentration (CMC) of the fatty acids used, and then investigated oligomer formation at
fatty acid concentrations below, near, and above the CMC. They found that below the
4

CMC for a given fatty acid, Aβ42 behaved the same way it did in controls containing no
fatty acid, and formed fibrils. Near the CMC, the rate of aggregation of Aβ increased
significantly, while above the CMC aggregation was inhibited. In the incubations with
fatty acid concentrations below the CMC, they found monomeric and fibril forms of Aβ,
just as they did in the control samples containing no fatty acid. Incubations near the
CMC produced 12-18mers, while concentrations above the CMC produced 4-5mers.
These two forms were found to consist mainly of β-sheets, having subtle structural
differences. Both forms were examined using atomic force microscopy. The control
samples showed clusters of fibrillar material, while the samples formed near the CMC
showed a mixture of fibrillar and small round particles. Samples produced above the
CMC showed only round particles. This finding demonstrated that oligomers produced
near and above the CMC are structurally different. The oligomers were also evaluated
for their ability to seed aggregation of other oligomers, and it was found that oligomers
produced near the CMC were able to speed up the aggregation of monomer, acting as a
seed, while oligomers produced above the CMC were not able to do so. The 4-5mers
were also found to be more thermodynamically stable than 12-18mers. These results
suggest that the formation of Aβ is dependent on the nature of the interface in which it is
formed. Different aggregate species form under micellar and non-micellar conditions.
Prion proteins and Aβ
Prions are a group of proteins capable of self-propagation through a templateassisted corruptive mechanism. Diseases resulting from prion activity include
Creutzfeldt-Jakob disease in humans, scrapie in sheep, and bovine spongiform
encephalopathy, better known as mad cow disease. 18 It has been observed that the
5

activity of Aβ in AD shares several characteristics with the prion diseases. For instance,
both diseases result from the buildup of abnormally-folded proteins in the brain, and
familial mutations in the proteins involved in each disease can predispose an individual to
developing that disease. 18 One important characteristic of prion diseases is that the
presence of the toxic, improperly-folded form of the involved protein can induce the
improper folding of the healthy form of the protein.
The focus of this project is on the observation and characterization of this same
type of self-seeding behavior in the Aβ protein. As already shown by Kumar et al,
oligomers formed in fatty acid are capable of seeding the aggregation of more Aβ. It is
therefore important that we characterize this self-seeding behavior, to determine whether
Aβ corruption occurs in a prion-type mechanism.

Materials and Methods
Materials
Aβ peptides were synthesized at the Mayo Clinic Peptide Synthesis Facility
(Rochester, MN) using Fmoc chemistry. The sodium salt of lauric acid was obtained
from NuCheck Prep Inc. (Elysian, MN). Sodium dodecyl sulfate (SDS) and all
antibodies were obtained from Sigma Aldrich (St. Louis, MO). Biotin was purchased
from Millipore (Billerica, MA). Streptavidin-HRP was purchased from Thermo
Scientific, and FITC was purchased from Fisher Scientific. All other chemicals were
purchased from VWR Inc.
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Preparation of Aβ monomers
Aβ peptide stocks were stored at -20°C. Samples of 0.7-1.4 mg of Aβ
were dissolved in 35 μL of 0.5 M NaOH, and allowed to stand at room temperature for 7
minutes. Next, 0.5 mL of nanopure water was added, and this stood at room temperature
for 10 minutes before size-exclusion chromatography (SEC) to isolate monomeric Aβ.
The sample was loaded onto a Superdex 75 10/300 GL column attached to an AKTA
FPLC system (GE Healthcare, Buckinghamshire). The column was run with 20 mM
TRIS at pH 8.0 at a flow rate of 0.5 mL/min, collecting 1 minute fractions. Fraction
concentrations were then determined by UV-Vis spectroscopy using a Cary 50
spectrophotometer (Varian Inc), and a molar extinction coefficient (ε) of 1490 cm-1 M-1
(www.expasy.org). Monomeric Aβ was stored at 4°C, and fractions were used within 3
days of preparation.
Examination of Stability of LFAOs with respect to temperature and buffer conditions
Wild-type Aβ42 monomer was prepared with various modifications of the
procedure described by Kumar et al. 17 Samples of 25 μM Aβ monomer were incubated
at room temperature, 4°C, and 37°C with either 5 mM or 20 mM lauric acid in 5 mM
TRIS and 50 mM NaCl for 24-48 hours. Alternately, samples containing monomer
incubated with 5 mM and 20 mM lauric acid were incubated in 1X phosphate-buffered
saline (PBS) at 37°C for 24-48 hours.
Generation of Large Fatty-Acid-Derived oligomers (LFAOs)
Wild-type Aβ42 LFAOs were prepared by incubating 50 μM Aβ42 monomer in 5
mM lauric acid and 50 mM NaCl in 20 mM TRIS (pH 8.0) for 48 hours at 37°C, as
7

described by Kumar, et al. 17 These were then isolated using SEC as described above,
and oligomers were collected from fractions 15-18.
The ideal fatty acid concentration for the generation of Aβ42 E22G oligomers was
determined by incubating E22G monomer in the above conditions, with concentrations of
5, 15, and 20 μM lauric acid. For all subsequent preparations, E22G monomer was
incubated in 15 mM lauric acid in the conditions described above. E22G oligomers were
isolated by SEC and collected from fractions 15-18. All isolated oligomers were stored
at 4°C.
Seeding reactions
Monomeric Aβ (20 μM) was incubated with concentrations of LFAOs ranging
from 0.4-3 μM in 20 mM TRIS (pH 8.0) for 72 hours at room temperature. Samples
were examined using polyacrylamide gel electrophoresis (PAGE) and immunoblotting.
Polyacrylamide gel electrophoresis (PAGE)
Samples were dissolved in 2-(N-morpholino)ethanesulfonic acid (MES) loading
buffer containing 1% SDS and loaded onto 4-20% NuPage gels (Novex or BioRad) along
with a dye-linked molecular weight marker. The gels were electrophoresed in Laemmli
running buffer containing 0.1% SDS. Gels were transferred onto 0.45 μm Immobilon®
nitrocellulose membranes (BioTraceTM NT, Life Sciences Inc.) for immunoblotting.
Immunoblotting
After transfer, nitrocellulose membranes were boiled for two minutes, then
incubated in blocking buffer containing 1X PBS, 5% nonfat dry milk, and 0.1% tween-20
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overnight. Blots were incubated in a solution containing 4 μL Ab9 monoclonal antibody,
1% blocking buffer, and 1X PBS for 1 hour. After rinsing with PBS to remove excess
primary antibody, blots were incubated with horseradish peroxidase conjugated antimouse IgG and developed with ECL reagent (Thermo Scientific).
Biotin labeling
Samples of Aβ peptide were dissolved in hexafluoro-2-propanol (HFIP) to obtain
a 1.3 mM solution, and then shaken at 37°C for 1½ hours before vacuum evaporation
until a film was formed. Films were then stored at -20°C until use. The films were resuspended in 100 μL of PBS. The films were re-suspended in 40 μL of PBS to obtain a
0.3 μM solution. Biotin was added to obtain a 1:10 ratio of Aβ to biotin and mixed by
vortexing. This was then allowed to sit at room temperature for 1 ½ hours before
purification. The labeled samples were then purified using a Hi Tap 5 mL desalting
column attached to an AKTA FPLC purification system in 20 mM TRIS (pH 8.0) at a
flow rate of 1 mL/min. Biotin-labeled peptide concentrations were estimated by UV-Vis
spectroscopy, and peptides were visualized using horseradish peroxidase (HRP)
conjugated streptavidin and ECL reagent, similar to the immunoblotting procedure
described above, but without the need for secondary antibody.

Results
LFAO formation is stable in a variety of experimental conditions
Aβ42 wild-type monomer was incubated at room temperature, 37 °C, and 4 °C in
Tris (pH 8.0), as well as in PBS (pH 8.0) at 37°C.
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Figure 1: Formation of
LFAOs
at
room
temperature, 37 °C, and 4
°C in Tris and PBS. M is
monomer incubated with
no fatty acid. Fatty acid
concentrations (mM) are
shown below lanes.

Incubation with 20 mM fatty acid produced distinct bands at 10 kDa, corresponding to
dimers, while incubations in 5 mM fatty acid produced bands at both 10 kDa (dimers)
and 15-30 kDa (3-7 mers) (with the exception of the incubation at 4°C, which formed a
15-18 kDa band (3-4 mers)) as shown in Figure 1. After 48 hours, the dimeric bands
disappeared, and more extensive oligomerization was achieved (data not shown). These
findings show us that LFAOs are stable at physiological temperature and pH, as well as
that they can be stored in a variety of temperature and buffer conditions.
Aβ42 Arctic (E22G) mutant forms LFAOs
Aβ42 E22G mutant peptide was incubated in
15 mM lauric acid and 50 mM NaCl in 20 mM Tris
(pH 8.0) for 48 hours at 37 °C. This produced
oligomers of 30-40 kDa corresponding to 6-9 mers as
Figure 2: Formation of Aβ42 E22G LFAOs. Lane marked "C"
shows E22G monomer with no fatty acid incubated for 48 hours at
37 °C. Lane marked "L" shows E22G LFAOs generated by
incubating Aβ42 E22G monomer with 15 mM lauric acid for 48
hours at 37 °C.
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shown in Figure 2. These LFAOs were isolated using SEC, and their concentrations
determined by UV-Vis spectroscopy before being used for subsequent seeding
experiments. The size similarity between wild-type and Arctic LFAOs seems to suggest
that Arctic LFAOs may also warrant examination for self-replication properties.

Aβ42 E22G oligomers are capable of
self-replication
When 20 μM Aβ42 E22G
monomer was incubated with Aβ42
E22G LFAOs, subsequent
immunoblotting revealed an 80-200 kDa
band (17-45 mers), which was larger
than the 30-40 kDa E22G LFAOs (6-9
mers). Fibrils, remaining monomer, and
small amounts of dimer were also
observed in the samples as shown in

Figure 3: Self-seeding of Aβ42 E22G, and cross-seeding
of E22G oligomer with Aβ42 wild-type. C represents
control sample with no added seed. Lanes labeled
“Seed” contained only oligomers. Numbers above lanes
are μM concentrations of oligomer.

Figure 3. The 30-40 kDa band corresponding to the E22G LFAOs originally used as
seeds was not observed in self-seeding samples of Aβ42 E22G monomer with Aβ42
E22G LFAOs. The signal strength of the bands increased with an increasing initial seed
concentration used, and the total signal strength for each seeded fraction was greater than
the signal strength of the LFAOs used as seeds, indicating that seeding took place.
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Aβ42 E22G oligomers cross-seed Aβ42 wild-type monomer
Cross-seeding of wild-type Aβ42 monomer with Aβ42 E22G LFAOs produced a
40-80 kDa band (8-18 mers), similar to the bands produced by both Aβ42 wild-type and
E22G oligomers as shown in Figure 3. These bands overlapped the size range of the
E22G LFAOs used for seeding. ECL signal increased as the concentration of seed used
increased.
Aβ42 E22G oligomers cross-seed Aβ40 E22G monomer
Cross-seeding of Aβ40 E22G
monomer with Aβ42 E22G oligomer
resulted in a band of 40-80 kDa (8-18
mers), similar to that of the E22G
oligomer seed. The signal strength of
the band increased with an increasing
seed concentration, and the overall
signal strength of each reaction was
stronger than its isolated seed alone as
shown in Figure 4. This increase in signal
strength indicates that the LFAO seeds the

Figure 4: Cross-seeding of Aβ40 E22G monomer with
wild-type Aβ42 LFAO. Lane M is Aβ40 monomer
alone. Increasing concentrations of E22G LFAO alone
are shown above. Increasing concentrations of LFAO
incubated with the same concentration of Aβ40 are
shown above lanes.

formation of more LFAO from the Aβ40 monomer.
Generation of biotin-labeled Aβ monomers
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In order to determine whether the increase in
signal strength observed in the seeding samples is due
to the conversion of monomer into the oligomeric
form, we sought to label the monomer with a
detectable tag which could be seen in the oligomeric

bands. Biotin, a protein tag that binds strongly to
streptavidin, was chosen because HRP conjugated
streptavidin could be used in Western blotting, and

Figure 5: Streptavidin labeling of wild-type
Aβ42 monomer. A sample of previously
labeled Aβ40 monomer was used for
control. Lane L shows the sample before
purification by desalting. Numbered lanes
correspond to SEC fractions.

the results visualized using ECL. Biotin labeling of Aβ monomer was confirmed using a
modified immunoblotting technique utilizing streptavidin-HRP. Blots were incubated
with streptavidin-HRP for one hour before visualization with ECL reagent. We were
able to detect monomeric bands via streptavidin binding, as well as with traditional
immunoblotting used to detect Aβ.
Biotin-labeled oligomer formation
To preliminarily determine the
detectability of the biotin label within LFAOs,
we prepared LFAOs using the above
described LFAO generation method,
incubating for 72 hours (LFAOs formation is
stable over 170 hours). 17 Biotin-labeled
oligomers were detected by both streptavidinHRP, and immunoblotting with Ab9 antibody.

Figure 6: Oligomer formation detected with Ab9
primary antibody, and streptavidin. M is Aβ42
biotin-labeled monomer alone. C is an Aβ40
biotin-labeled control. Numbers represent mM
concentrations of lauric acid. For Ab9 blot, lanes
not labeled "biotin" are control preparations
with 100% unlabeled Aβ42.
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At both 20 mM and 5 mM concentrations of fatty acid, 4-5 mers and 12-18 mers,
respectively, were detectable using both streptavidin and Ab9 primary antibody.
Self-propagation of biotin-labeled wild-type Aβ42 monomer with wild-type LFAO
A mixture of 10 μM biotin-labeled Aβ42 wild-type monomer and 10μM
unlabeled Aβ42 monomer (total
concentration of 20 μM) was incubated
with unlabeled LFAO seeds in
concentrations of 0.4 μM and 0.8 μM seed
for 96 hours at room temperature.
Detectable LFAO bands were observed
upon immunoblotting with Ab9, but only

monomeric bands were detected with
streptavidin as seen in Figure 7.

Figure 7: Seeding of biotin-labeled wt Aβ42 with wt
LFAO. Left, we see only monomer detected by
streptavidin-HRP. Right, we see both monomeric and
oligomeric bands detected with Ab9. M is biotinlabeled monomer alone. Numbers are concentrations
of LFAO seed in μM. Lanes marked S are LFAO seed
alone.

To ensure that the lack of
detectable oligomers in the biotin blot
was not due to some preferential seeding
of unlabeled monomer, we incubated
100% biotin-labeled wild-type Aβ42
monomer with LFAOS, and observed
with both Ab9 and streptavidin-HRP. We
were again only able to visualize monomer

Figure 8: Seeding of biotin-labeled wt Abeta42 with
wt LFAO. Numbers correspond to μM concentrations
of seed. Streptavidin-HRP detection is shown left.
Ab9 detection is shown right. Oligomeric bands are
observable in the gel blotted with Ab9.
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with streptavidin, while Ab9 detected oligomers as well. We concluded that the seeding
interaction must somehow block the binding site for biotin and streptavidin, and so we
were not able to use biotin labeling to confirm the incorporation of monomer into the
oligomeric form.
Discussion
One of the key distinguishing characteristics of prion diseases is their ability to
self-replicate. We have seen that when we seed Aβ monomers with LFAOs, oligomers of
the same molecular weight as the LFAOs are formed. In other words, LFAOs selfpropagate upon interacting with monomers. Mutant Aβ monomers and LFAOs also tend
to cross-seed to form oligomers of similar molecular weight. This suggests that LFAOs
could propagate via a prion-like mechanism. In order to further investigate this
propagation mechanism, further biophysical characterization of both the LFAOs and the
replicated oligomers is necessary. Particularly, it is important to ascertain the degree of
structural similarity between the LFAOs and the replicated oligomers. We should also
determine whether replicated oligomers, when isolated, are capable of seeding the
formation of more replicated oligomers. Continuous self-replication across multiple
generations would provide strong evidence that LFAOs replicate via a prion mechanism.
It is important to note that our biotin-labeling experiments revealed a dissimilarity
between LFAOs and replicated oligomers. While we were able to detect the biotin label
within LFAOs after generation with fatty acid, streptavidin-HRP could not detect the
replicated oligomers. This suggests that the binding site for streptavidin to biotin is
blocked in the replicated oligomers, but accessible in the LFAOs used for seeds. The
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degree of this structural difference is yet to be determined, but serves as evidence against
a prion mechanism for LFAO propagation.
Our LFAOs can only be considered to have potential biological relevance if they
are able to exist under physiological conditions. Kumar and co workers demonstrated the
formation of LFAOs using fatty acids, which are physiological molecules. 17 However, in
order to be considered important, LFAOs must not only be formed with the help of
physiological molecules, but also be stable under physiological conditions. We
determined that LFAOS are stable at physiological pH (37 °C) as well as nearphysiological pH (8.0). These findings serve as further evidence that LFAOs might exist
within the body, and play a role in AD pathology.
We have demonstrated that mutant E22G LFAOs, which may be involved in
CAA, seed the formation of LFAO-sized oligomers when incubated with wild-type Aβ42
monomer. Conversely, Aβ40 monomer oligomerization is less extensive, and E22G
monomer forms larger aggregates when self-seeded. This preferential seeding of Aβ42 to
form oligomers of the same molecular weight as LFAOs indicates a potential prion-like
mechanism for LFAO propagation in AD, which may be influenced by LFAOs of mutant
peptides involved in CAA. The formation of larger aggregates upon E22G self-seeding
indicates that the Arctic mutant may have a more additive aggregation effect. The
disappearance of the E22G LFAO bands from the self-seeding samples suggests that the
E22G monomer aggregates with the LFAO seeds to form larger oligomers.
Since we were unable to confirm the incorporation of Aβ monomer into LFAOsized aggregates using biotin labeling, further experimentation will focus on exploring
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other labeling techniques which may be able to show conclusively whether LFAO seeded
Aβ monomer is incorporated into the oligomeric form. One promising potential label is
FITC, a fluorescent molecule that binds to the amino terminus of the peptide. If FITC is
able to label the Aβ monomer without inhibiting aggregation, we will be able to examine
seeded oligomers using UV-Vis spectroscopy to determine whether FITC labeled Aβ
monomer is incorporated into seeded oligomers.
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